Clinical Trials Logo

Rift Valley Fever clinical trials

View clinical trials related to Rift Valley Fever.

Filter by:
  • None
  • Page 1

NCT ID: NCT05139524 Recruiting - Rift Valley Fever Clinical Trials

RVF and Other Emerging Infectious Diseases in East and Central Africa

Start date: October 8, 2021
Phase:
Study type: Observational

Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo

NCT ID: NCT04754776 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

Start date: June 11, 2021
Phase: Early Phase 1
Study type: Interventional

Phase I open label, non-randomised dose escalation study on healthy UK volunteers aged from 18 to 50 years to assess the safety and immunogenicity of ChAdOx1 RVF

NCT ID: NCT04672824 Completed - Rift Valley Fever Clinical Trials

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years

NCT ID: NCT03609398 Recruiting - Rift Valley Fever Clinical Trials

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

RVF
Start date: October 4, 2018
Phase: Phase 2
Study type: Interventional

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

NCT ID: NCT00869713 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

RVF
Start date: September 2009
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

NCT ID: NCT00584194 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

RVF
Start date: June 2004
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine

NCT ID: NCT00415051 Completed - Rift Valley Fever Clinical Trials

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

MP-12
Start date: August 2006
Phase: Phase 2
Study type: Interventional

This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.

NCT ID: NCT00287014 Completed - Rift Valley Fever Clinical Trials

Rift Valley Fever in Kenya

Start date: March 2006
Phase: N/A
Study type: Observational

The purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya. They will be given a questionnaire, undergo a medical examination that includes an eye exam, and have a 1-teaspoon sample of blood taken from a vein. Participation will take about 3 hours.